KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Staar Surgical (STAA) Gains from Sales and Divestitures (2021 - 2026)

Staar Surgical (STAA) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $16000.0 as the latest value for Q1 2026.

  • For the quarter ending Q1 2026, Gains from Sales and Divestitures fell 89.26% year-over-year to $16000.0, compared with a TTM value of $16000.0 through Jan 2026, down 89.26%, and an annual FY2026 reading of $16000.0, down 89.26% over the prior year.
  • Gains from Sales and Divestitures was $16000.0 for Q1 2026 at Staar Surgical, down from $277000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $277000.0 in Q3 2025 and bottomed at $5000.0 in Q3 2022.
  • Average Gains from Sales and Divestitures over 5 years is $60250.0, with a median of $27000.0 recorded in 2023.
  • The sharpest move saw Gains from Sales and Divestitures tumbled 90.74% in 2022, then skyrocketed 2880.0% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $5000.0 in 2022, then changed by 0.0% to $5000.0 in 2023, then surged by 2880.0% to $149000.0 in 2024, then surged by 85.91% to $277000.0 in 2025, then crashed by 94.22% to $16000.0 in 2026.
  • Business Quant data shows Gains from Sales and Divestitures for STAA at $16000.0 in Q1 2026, $277000.0 in Q3 2025, and $20000.0 in Q2 2025.